{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:57:52Z","timestamp":1780340272926,"version":"3.54.1"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1097\/mpa.0000000000000385","type":"journal-article","created":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T19:37:56Z","timestamp":1441481876000},"page":"32-39","source":"Crossref","is-referenced-by-count":17,"title":["Advances in Molecular Pathology and Treatment of Periampullary Cancers"],"prefix":"10.1097","volume":"45","author":[{"given":"Manju D.","family":"Chandrasegaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Sjoquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil D.","family":"Merrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210212","first-page":"543","article-title":"Periampullary cancers: are there differences Surg Clin North Am.","volume":"81","author":"Sarmiento","year":"2001","journal-title":""},{"key":"R2-5-20210212","first-page":"759","article-title":"Ampullary cancer-a separate clinical entity Histopathology.","volume":"64","author":"Perysinakis","year":"2014","journal-title":""},{"key":"R3-5-20210212","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.3748\/wjg.v20.i24.7849","article-title":"Personalising pancreas cancer treatment: when tissue is the issue.","volume":"20","author":"Sjoquist","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R4-5-20210212","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hpb.12078","article-title":"2564 resected periampullary adenocarcinomas at a single institution: trends over three decades.","volume":"16","author":"He","year":"2014","journal-title":"HPB (Oxford)"},{"key":"R5-5-20210212","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/hpb.12071","article-title":"Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas.","volume":"15","author":"Chen","year":"2013","journal-title":"HPB (Oxford)"},{"key":"R6-5-20210212","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12957-015-0498-5","article-title":"Distribution and pathological features of pancreatic, ampullary, biliary and duodenal cancers resected with pancreaticoduodenectomy.","volume":"13","author":"Chandrasegaram","year":"2015","journal-title":"World J Surg Oncol"},{"key":"R8-5-20210212","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archsurg.2007.17","article-title":"Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials.","volume":"143","author":"Butturini","year":"2008","journal-title":"Arch Surg"},{"key":"R9-5-20210212","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"key":"R10-5-20210212","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ajco.12062","article-title":"Cancer survival and prevalence in Australia: period estimates from 1982 to 2010.","volume":"9","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"R11-5-20210212","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014.","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R12-5-20210212","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00534-013-0610-6","article-title":"Understanding pancreatic cancer genomes.","volume":"20","author":"Cowley","year":"2013","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R13-5-20210212","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"R14-5-20210212","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.gde.2013.12.001","article-title":"Pancreatic cancer genomics.","volume":"24","author":"Chang","year":"2014","journal-title":"Curr Opin Genet Dev"},{"key":"R15-5-20210212","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes.","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"R16-5-20210212","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"R17-5-20210212","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"R18-5-20210212","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jjco\/hym178","article-title":"Randomised phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).","volume":"38","author":"Maeda","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"R19-5-20210212","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/bjc.2013.722","article-title":"Adjuvant chemotherapy in elderly patients with pancreatic cancer.","volume":"110","author":"Nagrial","year":"2014","journal-title":"Br J Cancer"},{"key":"R20-5-20210212","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"R21-5-20210212","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).","volume":"28","author":"Kindler","year":"2010","journal-title":"J Clin Oncol"},{"key":"R22-5-20210212","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.","volume":"28","author":"Philip","year":"2010","journal-title":"J Clin Oncol"},{"key":"R23-5-20210212","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"R24-5-20210212","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R25-5-20210212","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"R26-5-20210212","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"key":"R27-5-20210212","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12029-013-9561-z","article-title":"Recent treatment advances and novel therapies in pancreas cancer: a review.","volume":"45","author":"Valsecchi","year":"2014","journal-title":"J Gastrointest Cancer"},{"issue":"suppl 2","key":"R28-5-20210212","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/annonc\/mdu193.3","article-title":"NAPOLI-1: randomized phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy.","volume":"25","author":"Von Hoff","year":"2014","journal-title":"Ann Oncol"},{"key":"R29-5-20210212","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clon.2014.06.003","article-title":"Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer.","volume":"26","author":"Sen","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R32-5-20210212","first-page":"1201","article-title":"Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.","volume":"17","author":"Mori","year":"2007","journal-title":"Oncol Rep"},{"key":"R33-5-20210212","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bjc.6603559","article-title":"Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.","volume":"96","author":"Nakano","year":"2007","journal-title":"Br J Cancer"},{"key":"R34-5-20210212","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.","volume":"136","author":"Farrell","year":"2009","journal-title":"Gastroenterology"},{"key":"R35-5-20210212","doi-asserted-by":"crossref","first-page":"djt347","DOI":"10.1093\/jnci\/djt347","article-title":"Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.","volume":"106","author":"Greenhalf","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R36-5-20210212","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/annonc\/mdt270","article-title":"Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).","volume":"24","author":"Fensterer","year":"2013","journal-title":"Ann Oncol"},{"key":"R38-5-20210212","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00000658-199807000-00013","article-title":"Factors predictive of survival in ampullary carcinoma.","volume":"228","author":"Howe","year":"1998","journal-title":"Ann Surg"},{"key":"R39-5-20210212","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0039-6060(05)80197-7","article-title":"Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival.","volume":"117","author":"Allema","year":"1995","journal-title":"Surgery"},{"key":"R40-5-20210212","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1245\/s10434-008-9886-1","article-title":"Survival after resection of ampullary carcinoma: a national population-based study.","volume":"15","author":"OConnell","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R41-5-20210212","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/01.sla.0000167853.04171.bb","article-title":"Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy.","volume":"242","author":"Yoon","year":"2005","journal-title":"Ann Surg"},{"key":"R43-5-20210212","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"key":"R44-5-20210212","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.2012.46.8868","article-title":"Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of Vater.","volume":"31","author":"Chang","year":"2013","journal-title":"J Clin Oncol"},{"key":"R45-5-20210212","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00000478-200303000-00003","article-title":"CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.","volume":"27","author":"Werling","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R46-5-20210212","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/01.MP.0000086073.92773.55","article-title":"Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays.","volume":"16","author":"Moskaluk","year":"2003","journal-title":"Mod Pathol"},{"key":"R47-5-20210212","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1309\/9R6673QEC06D86Y4","article-title":"Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study.","volume":"122","author":"Lau","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"R48-5-20210212","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/modpathol.2013.185","article-title":"Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.","volume":"27","author":"Mikhitarian","year":"2014","journal-title":"Mod Pathol"},{"key":"R49-5-20210212","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.humpath.2012.11.006","article-title":"Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.","volume":"44","author":"Voss","year":"2013","journal-title":"Hum Pathol"},{"key":"R50-5-20210212","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumour genotyping.","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"R51-5-20210212","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/ijc.27910","article-title":"KRAS GA mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma.","volume":"132","author":"Fu","year":"2013","journal-title":"Int J Cancer"},{"key":"R52-5-20210212","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1158\/1078-0432.CCR-12-0707","article-title":"CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation, constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.","volume":"18","author":"Fu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R53-5-20210212","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MPA.0b013e3182327a03","article-title":"EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer.","volume":"41","author":"Oliveira-Cunha","year":"2012","journal-title":"Pancreas"},{"key":"R54-5-20210212","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/MPA.0b013e31823cd9df","article-title":"Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.","volume":"41","author":"Schultz","year":"2012","journal-title":"Pancreas"},{"key":"R55-5-20210212","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jso.23529","article-title":"Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma.","volume":"109","author":"Shaib","year":"2014","journal-title":"J Surg Oncol"},{"key":"R56-5-20210212","doi-asserted-by":"crossref","first-page":"112","DOI":"10.14694\/EdBook_AM.2014.34.112","article-title":"Ampullary cancer: an overview.","volume":"34","author":"Ahn","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R57-5-20210212","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/annonc\/mdt191","article-title":"A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.","volume":"24","author":"Jiang","year":"2013","journal-title":"Ann Oncol"},{"key":"R58-5-20210212","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","article-title":"Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.","volume":"27","author":"Overman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R59-5-20210212","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s12032-009-9351-4","article-title":"The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.","volume":"27","author":"Kim","year":"2010","journal-title":"Med Oncol"},{"key":"R60-5-20210212","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdq038","article-title":"Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.","volume":"21","author":"Zaanan","year":"2010","journal-title":"Ann Oncol"},{"key":"R61-5-20210212","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.3748\/wjg.14.6458","article-title":"Cholangiocarcinoma: a compact review of the literature.","volume":"14","author":"Ustundag","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R62-5-20210212","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/cncr.27955","article-title":"KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.","volume":"119","author":"Hsu","year":"2013","journal-title":"Cancer"},{"key":"R63-5-20210212","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"key":"R64-5-20210212","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Eng J Med"},{"issue":"suppl 4","key":"R65-5-20210212","first-page":"iv210","article-title":"A multi-centre, phase II, open-label, single arm study of panitumumab, cisplatin and gemcitabine in biliary tract cancer: preliminary results of the AGITG TACTIC study.","volume":"25","author":"Shannon","year":"2014","journal-title":"Ann Oncol"},{"key":"R66-5-20210212","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"R67-5-20210212","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1158\/1055-9965.EPI-10-0328","article-title":"Small intestinal cancer: a population based study of incidence and survival patterns in the United States, 1992 to 2006.","volume":"19","author":"Qubaiah","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R68-5-20210212","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/j.canep.2012.01.008","article-title":"Incidence patterns of small bowel cancer in a population-based study in Sweden: increase in duodenal adenocarcinoma.","volume":"36","author":"Lu","year":"2012","journal-title":"Cancer Epidemiol"},{"key":"R69-5-20210212","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/COC.0b013e31821dee31","article-title":"Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience.","volume":"35","author":"Kim","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"R70-5-20210212","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000328506","article-title":"Adjuvant chemotherapy for small bowel adenocarcinoma after curative surgery.","volume":"80","author":"Koo","year":"2011","journal-title":"Oncology"},{"key":"R71-5-20210212","first-page":"495","article-title":"A case of primary duodenal cancer recurrence successfully treated with CapeOX therapy in Japanese.","volume":"41","author":"Miyamoto","year":"2014","journal-title":"Gan To Kagaku Ryoho"},{"key":"R72-5-20210212","first-page":"1726","article-title":"A case of recurrent duodenal carcinoma successfully controlled with FOLFOX treatment.","volume":"40","author":"Yasui","year":"2013","journal-title":"Gan To Kagaku Ryoho"},{"key":"R73-5-20210212","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","article-title":"A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.","volume":"23","author":"Xiang","year":"2012","journal-title":"Anticancer Drugs"},{"key":"R74-5-20210212","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11605-011-1667-7","article-title":"Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy.","volume":"16","author":"Onkendi","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"R75-5-20210212","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s11605-009-0953-0","article-title":"Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen.","volume":"13","author":"Manfredi","year":"2009","journal-title":"J Gastrointest Surg"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000000385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T13:07:06Z","timestamp":1653138426000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-201601000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000000385","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}